{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/ovarian-cancer/management/managing-a-woman-with-suspected-ovarian-cancer/","result":{"pageContext":{"chapter":{"id":"e47609d5-133b-5929-ad56-44ab30116871","slug":"managing-a-woman-with-suspected-ovarian-cancer","fullItemName":"Scenario: Managing a woman with suspected ovarian cancer","depth":2,"htmlHeader":"<!-- begin field 4313e3b6-34b4-425b-b3ff-32cf9b864751 --><h2>Scenario: Managing a woman with suspected ovarian cancer</h2><!-- end field 4313e3b6-34b4-425b-b3ff-32cf9b864751 -->","summary":"Covers recommended examination, tests, and referral that can be done in primary care for a woman in whom ovarian cancer is suspected.","htmlStringContent":"<!-- begin item bdfe06ea-e6c1-4064-8176-33ea7900d0cf --><!-- begin field 6afa58f3-076a-4756-9931-acbc0156311b --><p>From age 18 years onwards (Female).</p><!-- end field 6afa58f3-076a-4756-9931-acbc0156311b --><!-- end item bdfe06ea-e6c1-4064-8176-33ea7900d0cf -->","topic":{"id":"e76d1533-c4e4-5615-b47d-b9a78e802a8c","topicId":"2b5f9995-52a6-4997-b11b-4dd86f5b4cac","topicName":"Ovarian cancer","slug":"ovarian-cancer","lastRevised":"Last revised in July 2018","chapters":[{"id":"00f52bf3-2854-5c26-896d-9e19a7a50ffa","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"1978d14c-1832-5012-aad2-ae688f64a4f0","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"39ed13eb-bf02-5897-9546-f63bb13e1312","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"b6205ec5-8fed-5fa0-9459-17c9ed9797a4","slug":"changes","fullItemName":"Changes"},{"id":"dff67d8b-2740-5711-b49a-d03a83243ab3","slug":"update","fullItemName":"Update"}]},{"id":"4d027c28-c2b3-5578-8eab-c2029d5b3347","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"f40d2697-554a-5249-abb4-6247e9db5eca","slug":"goals","fullItemName":"Goals"},{"id":"6b3fba32-56cd-5102-879a-64cb859b80ef","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"8e5550d6-e4d8-54a5-8046-0542cdf4be38","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"c7811d8a-c44d-5470-8e72-e0a8ff4d2d61","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"816a9080-6571-5a58-bfe1-04411127e3d2","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"4afe1f86-c28e-51bf-8c7f-39373606165d","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"39f05ca6-5cf0-5e67-af39-03983de815d1","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"03b4909c-fc38-5af3-848f-1df54131e0c5","slug":"definition","fullItemName":"Definition"},{"id":"83553e71-1f1a-543b-be50-09b4c7b8c224","slug":"incidence","fullItemName":"Incidence"},{"id":"c8597bdc-f028-5141-85c3-c6b429bf7d78","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"e5f859f0-168b-5395-a133-af2778a0ef84","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"4d5f7685-3efd-5198-90e1-d8cb8f470a28","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"26a540a4-c12b-5ae8-b3de-eb2d3472a824","slug":"when-to-suspect-ovarian-cancer","fullItemName":"When to suspect ovarian cancer"},{"id":"d7d39f7a-9f30-588c-9589-b8c8b5a76729","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"d02788d8-8b2d-5672-8eca-dfcc643a2055","fullItemName":"Management","slug":"management","subChapters":[{"id":"e47609d5-133b-5929-ad56-44ab30116871","slug":"managing-a-woman-with-suspected-ovarian-cancer","fullItemName":"Scenario: Managing a woman with suspected ovarian cancer"}]},{"id":"99dcdee4-9931-5ef8-a3d8-d86417646b02","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"9b4bd4c6-cb71-5783-8529-7346c25fc30f","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"11ba9663-4a8b-516e-a825-1f8d766c7041","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"ec67bf69-9ccc-5c53-81da-f2c0713d4527","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"bcf5ab6b-23af-5b9a-bbcd-22d0002e20cf","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"ac95df2b-f68f-5f64-bb51-88ff094f74b8","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"23bfe348-903c-5728-b9b9-71e7975e7e53","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"faaa4aff-4567-544b-af9e-b7dc24fae5df","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"d02788d8-8b2d-5672-8eca-dfcc643a2055","slug":"management","fullItemName":"Management"},"subChapters":[{"id":"8682ffcd-af99-5ac0-bf71-c5a27d0ec9ee","slug":"management","fullItemName":"Management","depth":3,"htmlHeader":"<!-- begin field 9cf9d53e-b0cd-4931-b21f-aab41d67bd71 --><h3>How should I manage a woman with suspected ovarian cancer?</h3><!-- end field 9cf9d53e-b0cd-4931-b21f-aab41d67bd71 -->","summary":null,"htmlStringContent":"<!-- begin item 52e41d2f-b738-4c25-9e6d-c2ac870975fc --><!-- begin field 77382032-878d-46b4-a300-5dd4a8f3daeb --><ul><li><strong>Carry out an abdominal and pelvic examination.</strong><ul><li>If there is ascites, or a pelvic or abdominal mass (which is not caused by known uterine fibroids), refer the woman urgently to gynaecology (to be seen within 2 weeks) for further investigation.</li></ul></li><li><strong>If the examination is normal, measure serum CA125 concentration.</strong><ul><li><strong>If serum CA125 concentration is raised (35 IU/mL or greater), arrange an urgent ultrasound scan of the abdomen and pelvis.</strong><ul><li>If the ultrasound is suggestive of ovarian cancer, refer the woman urgently to gynaecology (to be seen within 2 weeks) for further investigation.</li></ul></li><li><strong>If serum CA125 is normal (less than 35 IU/mL), or raised (35 IU/mL or greater) but with a normal ultrasound:</strong><ul><li>Consider <a class=\"topic-reference internal-reference\" href=\"/topics/ovarian-cancer/diagnosis/differential-diagnosis/\">other causes for symptoms or a raised CA125</a>.</li><li>If no other clinical cause is apparent, advise the woman to return for review if her symptoms become more frequent and/or persistent.</li></ul></li></ul></li></ul><!-- end field 77382032-878d-46b4-a300-5dd4a8f3daeb --><!-- end item 52e41d2f-b738-4c25-9e6d-c2ac870975fc -->","subChapters":[{"id":"2dac1733-f91f-5b94-b738-b5180c754f1e","slug":"basis-for-recommendation-20c","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 40239abc-9901-43a1-8556-ba03d177fc65 --><h4>Basis for recommendation</h4><!-- end field 40239abc-9901-43a1-8556-ba03d177fc65 -->","summary":null,"htmlStringContent":"<!-- begin item 20c3e6ac-a3ad-4448-9fe8-4816a55b0ca2 --><!-- begin field f358aced-09fa-4cb1-ae86-b4c49364075b --><p>These recommendations are based on the National Institute for Health and Clinical Excellence (NICE) guideline <em>Ovarian cancer: the recognition and initial management of ovarian cancer </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/ovarian-cancer/references/\">National Collaborating Centre for Cancer, 2011</a>].</p><h5>Abdominal and pelvic examination</h5><ul><li>NICE based this recommendation on a systematic review of five studies (n = 2289) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/ovarian-cancer/references/\">Myers et al, 2006</a>], which found that pelvic examination identifies just under 50% of all pelvic masses.<ul><li>The pooled sensitivity was 45% (95% CI 28% to 68%).</li><li>The pooled specificity was 90% (95% CI 80% to 96%).</li></ul></li></ul><h5>Testing serum CA125 </h5><ul><li>NICE based this recommendation on indirect evidence from two systematic reviews [<a class=\"bibliography-reference internal-reference\" href=\"/topics/ovarian-cancer/references/\">Myers et al, 2006</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/ovarian-cancer/references/\">Medeiros et al, 2009</a>], which looked at the discrimination of malignant tumours from benign tumours by serum CA125 measurement in women who had a suspected adnexal mass on examination.<ul><li>The NICE guideline development group (GDG) acknowledged that the clinical evidence was of limited applicability because it did not come from symptomatic women in primary care, where the prevalence of ovarian cancer is lower. However, sensitivity analysis showed that changing the prevalence did not significantly affect the results; therefore, the GDG felt it was appropriate to use this data. Using a CA125 level of 35 U/mL or more to signify malignancy:<ul><li>Estimated specificity was 78% (95% CI 71% to 82%) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/ovarian-cancer/references/\">Myers et al, 2006</a>] and 75% (95% CI 73% to 77%) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/ovarian-cancer/references/\">Medeiros et al, 2009</a>].</li><li>Estimated sensitivity was 78% (95% CI 75% to 81%) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/ovarian-cancer/references/\">Myers et al, 2006</a>] and 80% (95% CI  76% to 82%) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/ovarian-cancer/references/\">Medeiros et al, 2009</a>].</li></ul></li></ul></li></ul><h5>Pelvic ultrasound</h5><ul><li>NICE based this recommendation on indirect evidence from three systematic reviews, which found that in the detection of ovarian cancer combined Doppler and morphometric ultrasound had [<a class=\"bibliography-reference internal-reference\" href=\"/topics/ovarian-cancer/references/\">National Collaborating Centre for Cancer, 2011</a>]:<ul><li>A sensitivity that ranged from 87% to 92% between the three studies.</li><li>A specificity that ranged between 88% and 92% between the three studies.</li></ul></li></ul><!-- end field f358aced-09fa-4cb1-ae86-b4c49364075b --><!-- end item 20c3e6ac-a3ad-4448-9fe8-4816a55b0ca2 -->","subChapters":[]}]}]}}},"staticQueryHashes":["3666801979"]}